Novlead Biotech Raises ￥10M in Series A, Accelerating the Medical Applications of NO

(VCBeat) Jan 13, 2021 -- Novlead Biotechnology Co., Ltd. ("Novlead Biotech") has announced a Series A funding round of tens of millions of yuan, led by the new investor Northern Light Venture Capital with participation from the existing investor InnoMed Capital. The fresh round of funding will be used for the clinical trials of Novlead Biotech's Class III medical devices for inhaled NO (iNO) therapy.

Previously, Novlead Biotech completed an angel round of financing by InnoMed Capital at the end of 2019.

"From the angel round to Series A, Novlead Biotech has made an astonishing achievement in just over one year. We have developed two NO generators, and the flagship product is about to enter into clinical trials," Dr. Wen Mao, CEO of Novlead Biotech, said, "Our portable NO generator is the world's first Class III medical device to produce real-time NO gas based on electrochemistry and catalytic technology, which can be used independently or in combination with multiple ventilators. The device ensures the production of high-purity NO gas by the unique micro-release controlled reactor through precise control of raw material and proportion. Novlead Biotech's technological innovation enables iNO therapy to have great price-performance ratio and adapt to the future medical pricing system in China."

The technology adopted by Novlead Biotech is a breakthrough achievement in the field of iNO therapy in the past decades. Its unique portable electrochemical technology provides the real-time generation of NO gas. Its ventilator technology can realize the real-time monitoring of the patient's breathing mode and ensure the stability and safety of NO release. 

At the same time, Novlead Biotech's new products are under development, indications covering asthma, diabetic foot, pulmonary fibrosis, chronic obstructive emphysema, etc., which marks the transition to a provider of a full range of applications in the field of iNO therapy.

Founded in 2005, Northern Light is a venture capital firm targeting early-stage opportunities of innovation and disruptive technology. The company manages 5 USD funds and 5 RMB funds with a total amount of US$4.5 billion. Northern Light focuses on 3 main sectors including TMT, advanced technology, and healthcare.

InnoMed Capital, registered in Nanjing Jiangbei New Area, is mainly engaged in equity investment and fund management, etc. The main investment directions of funds managed by InnoMed Capital are strategic emerging industries such as semiconductors, integrated circuits, new-generation information technology, intelligent manufacturing, military equipment, and biomedicine.